Skip to main content

Table 3 Therapy in patients whose tumors had low and high-grade infection with human cytomegalovirus Immediate-early (IEA) and late antigen (LA)

From: Low levels of Human Cytomegalovirus Infection in Glioblastoma multiforme associates with patient survival; -a case-control study

Therapy Low-grade HCMV-IEA (n = 19) High-grade HCMV-IEA (n = 61) Low-grade HCMV-LA (n = 33) High-grade HCMV-LA (n = 47)
Gamma knife 7 (37%) 10 (16.4%) 10 (30%) 7 (15%)
RT + adjuvant chemotherapy 7 (37%) 28 (46%) 14 (42%) 21 (45%)
Adjuvant chemotherapy 2 (11%) 7 (11%) 2 (6%) 7 (15%)
RT + Temozolomide 2 (11%) 8 (13%) 4 (12%) 6 (13%)
RT 1 (5.3%) 3 (5%) 1 (3%) 3 (6%)
RT + Lumostin 0 (0%) 1 (2%) 0 (0%) 1 (2%)
RT + IRESSA 0 (0%) 2 (3%) 2 (6%) 0 (0%)
Cortisone 0 (0%) 1 (2%) 1 (3%) 0 (0%)
Palliative therapy 0 (0%) 4 (7%) 1 (3%) 3 (6%)